Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .
The effect of different doses of fluvastatin on inflammatory markers in the early phase of acute coronary syndrome.
BACKGROUND Inflammation promotes acute coronary syndromes ( ACS ) and ensuing clinical complications . It is well known that statins decrease the risk of coronary events and may benefit the stabilization of atherosclerotic plaque with their anti-inflammatory effects . We investigated the effects of different doses of fluvastatin on serum concentrations of high-sensitive C-reaction protein ( hs-CRP ) and tumor necrosis factor-alpha ( TNF-alpha ) in the early phase of ACS . METHODS We prospect ively r and omized 60 patients with ACS to 3 groups : ( 1 ) group A ( n=20 ) : were given routine therapy ; ( 2 ) group B ( n=20 ) : were administrated routine therapy with 40 mg/d oral fluvastatin ;  ( 3 ) group C ( n=20 ) : received routine therapy with 80 mg/d oral fluvastatin .  Twenty patients with stable coronary heart disease served as controls . The following-up period was 7 days . By immunoturbidimetric assay and ELISA methods the serum concentrations of hs-CRP and TNF-alpha were measured before and after therapy . RESULTS ( 1 ) The serum concentrations of hs-CRP and TNF-alpha in patients with ACS was significantly higher than those in the control group ( P<0.05 ) . ( 2 ) After 1 week of therapy , the serum concentrations of hs-CRP and TNF-alpha were significantly lower in group B and group C ( all P<0.01 ) , especially in group C. ( 3 ) The serum concentrations of hs-CRP and TNF-alpha did not correlate to the concentrations of TC , TG , LDL-C , or HDL-C. CONCLUSION Early fluvastatin intervention decreases dose-dependently the serum concentrations of hs-CRP and TNF-alpha of patients with ACS . The high-dose fluvastatin invention may play a stronger anti-inflammatory effect in ACS patients . The anti-inflammatory effect of fluvastatin may be beyond the lipid lowering
Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .